Literature DB >> 9457475

Neurogenic vasodilatation and plasma leakage in the skin.

P Holzer1.   

Abstract

1. Primary afferent nerve fibers control cutaneous blood flow and vascular permeability by releasing vasoactive peptides. These vascular reactions and the additional recruitment of leukocytes are commonly embodied in the term neurogenic inflammation. 2. Calcitonin gene-related peptide (CGRP) acting via CGRP1 receptors is the principal transmitter of neurogenic dilatation of arterioles whereas substance P (SP) and neurokinin A (NKA) acting via NK1 receptors mediate the increase in venular permeability. 3. Neurogenic vasodilatation and plasma protein leakage play a role in inflammation because many inflammatory and immune mediators including interleukin-1 beta, nitric oxide, prostanoids, protons, bradykinin, histamine, and 5-hydroxytryptamine can stimulate peptidergic afferent nerve fibers or enhance their excitability. 4. Neurogenic inflammatory reactions can be suppressed by alpha 2-adrenoceptor agonists, histamine acting via H1 receptors, 5-hydroxytryptamine acting via 5-HT1B receptors, opioid peptides, and somatostatin through prejunctional inhibition of peptide release from vasoactive afferent nerve fibers. CGRP, SP, and NKA receptor antagonists are powerful pharmacological tools to inhibit neurogenic inflammation at the postjunctional level. 5. Imbalance between the facilitatory and inhibitory influences on afferent nerve activity has a bearing on chronic inflammatory disease. Impaired nerve function represents a deficit in skin homeostasis while neuronal overactivity is a factor in allergic and hyperreactive disorders of the skin.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9457475     DOI: 10.1016/s0306-3623(97)00078-5

Source DB:  PubMed          Journal:  Gen Pharmacol        ISSN: 0306-3623


  102 in total

1.  Inhibition of stimulated meningeal blood flow by a calcitonin gene-related peptide binding mirror-image RNA oligonucleotide.

Authors:  Thomas Denekas; Markus Tröltzsch; Axel Vater; Sven Klussmann; Karl Messlinger
Journal:  Br J Pharmacol       Date:  2006-04-24       Impact factor: 8.739

Review 2.  Protease-activated receptor 2 signaling in inflammation.

Authors:  Andrea S Rothmeier; Wolfram Ruf
Journal:  Semin Immunopathol       Date:  2011-10-06       Impact factor: 9.623

Review 3.  Chronic orthostatic intolerance and the postural tachycardia syndrome (POTS).

Authors:  Julian M Stewart
Journal:  J Pediatr       Date:  2004-12       Impact factor: 4.406

Review 4.  Chemokines: integrators of pain and inflammation.

Authors:  Fletcher A White; Sonia K Bhangoo; Richard J Miller
Journal:  Nat Rev Drug Discov       Date:  2005-10       Impact factor: 84.694

5.  Sleep-inducing effect of substance P-cholera toxin A subunit in mice.

Authors:  Mark R Zielinski; Dmitry Gerashchenko
Journal:  Neurosci Lett       Date:  2017-09-01       Impact factor: 3.046

Review 6.  CGRP and migraine: could PACAP play a role too?

Authors:  Eric A Kaiser; Andrew F Russo
Journal:  Neuropeptides       Date:  2013-10-23       Impact factor: 3.286

7.  Substance P enhances wound closure in nitric oxide synthase knockout mice.

Authors:  Pornprom Muangman; Richard N Tamura; Lara A Muffley; F Frank Isik; Jeffrey R Scott; Chengyu Xie; Gary Kegel; Stephen R Sullivan; Zhi Liang; Nicole S Gibran
Journal:  J Surg Res       Date:  2008-05-16       Impact factor: 2.192

8.  Evidence for the role of neurogenic inflammation components in trypsin-elicited scratching behaviour in mice.

Authors:  R Costa; D M Marotta; M N Manjavachi; E S Fernandes; J F Lima-Garcia; A F Paszcuk; N L M Quintão; L Juliano; S D Brain; J B Calixto
Journal:  Br J Pharmacol       Date:  2008-05-05       Impact factor: 8.739

9.  Suppression of central taste transmission by oral capsaicin.

Authors:  Christopher T Simons; Yves Boucher; E Carstens
Journal:  J Neurosci       Date:  2003-02-01       Impact factor: 6.167

Review 10.  Neurogenic inflammation in fibromyalgia.

Authors:  Geoffrey Littlejohn; Emma Guymer
Journal:  Semin Immunopathol       Date:  2018-03-19       Impact factor: 9.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.